

RECEIVED  
CENTRAL FAX CENTER

AUG 10 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL  
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages In This Submission

8

Application Number	09/315,292
Filing Date	05/20/1999
First Named Inventor	C. Frank Bennett
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISIS-3561

## ENCLOSURES (Check all that apply)


- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Preliminary Amendment
- ☒ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation
- ☐ Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) \_\_\_\_\_
- ☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) (please identify below):


Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Isis Pharmaceuticals, Inc.		
Signature			
Printed name	Colleen J. McKiernan, Ph.D.		
Date	Aug 10, 2006	Reg. No.	48,570

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Colleen McKiernan	Date	Aug 10, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED  
CENTRAL FAX CENTER

DOCKET NO.: ISIS-3561

AUG 10 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Bennett et al.**

Serial No.: **09/315,292**

Group Art Unit: **1635**

Filed: **May 20, 1999**

Examiner: **Amy Hudson Bowman**

For: **COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY  
OF NUCLEIC ACIDS**

I, Colleen McKiernan, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, or being transmitted by facsimile to number 571-273-8300.

On August 10, 2006



Assistant Commissioner for Patents  
Mail Stop- No Fee Amendment  
PO Box 1450  
Alexandria, VA 22313-1450

Attn: EXAMINER BOWMAN

**AMENDMENT AND REQUEST FOR CONTINUED EXAMINATION**

In response to the Final Office Action dated May 10, 2006, in connection with the above-identified patent application. Applicants respectfully request the entry of the below amendments and reconsideration of the rejection in view of the following remarks.

Amendments to the claims start on page 2.

Remarks start on page 4.